IL-7 abrogates the immunosuppressive function of human double-negative T cells by activating Akt/mTOR signaling

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3139-3148

  Allgäuer, Andrea ^a   Schreiner, Elisabeth ^a   Ferrazzi, Fulvia ^a   Ekici, Arif B ^a   Gerbitz, Armin ^a   Mackensen, Andreas ^a   Völkl, Simon ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 7; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; IL7 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CELL SURVIVAL; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; DOUBLE NEGATIVE T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONTROL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL PROLIFERATION; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANTIGENS, CD4; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84942475169     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501389     Document Type: Article

References (50)

1. Zhang, Z. X., L. Yang, K. J. Young, B. DuTemple, and L. Zhang. 2000. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat. Med. 6: 782-789.
2. Fischer, K., S. Voelkl, J. Heymann, G. K. Przybylski, K. Mondal, M. Laumer, L. Kunz-Schughart, C. A. Schmidt, R. Andreesen, and A. Mackensen. 2005. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(2)CD82 double-negative regulatory T cells. Blood 105: 2828-2835.
3. Chen, W., M. S. Ford, K. J. Young, M. I. Cybulsky, and L. Zhang. 2003. Role of double-negative regulatory T cells in long-term cardiac xenograft survival. J. Immunol. 170: 1846-1853.
4. Young, K. J., L. S. Kay, M. J. Phillips, and L. Zhang. 2003. Antitumor activity mediated by double-negative T cells. Cancer Res. 63: 8014-8021.
5. Young, K. J., B. DuTemple, M. J. Phillips, and L. Zhang. 2003. Inhibition of graftversus-host disease by double-negative regulatory T cells. J. Immunol. 171: 134-141.
6. Ford, M. S., W. Chen, S. Wong, C. Li, R. Vanama, A. R. Elford, S. L. Asa, P. S. Ohashi, and L. Zhang. 2007. Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. Eur. J. Immunol. 37: 2234-2241.
7. Duncan, B., C. Nazarov-Stoica, J. Surls, M. Kehl, C. Bona, S. Casares, and T. D. Brumeanu. 2010. Double negative (CD3+ 42 82) TCR alphabeta splenic cells from young NOD mice provide long-lasting protection against type 1 diabetes. PLoS One 5: e11427.
8. Zhang, Z. X., Y. Ma, H. Wang, J. Arp, J. Jiang, X. Huang, K. M. He, B. Garcia, J. Madrenas, and R. Zhong. 2006. Double-negative T cells, activated by xenoantigen, lyse autologous B and T cells using a perforin/granzyme-dependent, Fas-Fas ligand-independent pathway. J. Immunol. 177: 6920-6929.
9. Ye, H., Y. Chang, X. Zhao, and X. Huang. 2011. Characterization of CD3+CD42CD82 (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation. Transpl. Immunol. 25: 180-186.
10. McIver, Z., B. Serio, A. Dunbar, C. L. O'Keefe, J. Powers, M. Wlodarski, T. Jin, R. Sobecks, B. Bolwell, and J. P. Maciejewski. 2008. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br. J. Haematol. 141: 170-178.
11. Voelkl, S., R. Gary, and A. Mackensen. 2011. Characterization of the immunoregulatory function of human TCR-ab+ CD42 CD82 double-negative T cells. Eur. J. Immunol. 41: 739-748.
12. Chetoui, N., M. Boisvert, S. Gendron, and F. Aoudjit. 2010. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 130: 418-426.
13. Schluns, K. S., W. C. Kieper, S. C. Jameson, and L. Lefrancois. 2000. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat. Immunol. 1: 426-432.
14. Tan, J. T., E. Dudl, E. LeRoy, R. Murray, J. Sprent, K. I. Weinberg, and C. D. Surh. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 98: 8732-8737.
15. Calzascia, T., M. Pellegrini, A. Lin, K. M. Garza, A. R. Elford, A. Shahinian, P. S. Ohashi, and T. W. Mak. 2008. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc. Natl. Acad. Sci. USA 105: 2999-3004.
16. Ponchel, F., R. J. Cuthbert, and V. Goëb. 2011. IL-7 and lymphopenia. Clin. Chim. Acta 412: 7-16.
17. Thiant, S., I. Yakoub-Agha, L. Magro, J. Trauet, V. Coiteux, J. P. Jouet, J. P. Dessaint, and M. Labalette. 2010. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant. 45: 1546-1552.
18. Malaspina, A., S. Moir, D. G. Chaitt, C. A. Rehm, S. Kottilil, J. Falloon, and A. S. Fauci. 2007. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 109: 2086-2088.
19. Dean, R. M., T. Fry, C. Mackall, S. M. Steinberg, F. Hakim, D. Fowler, J. Odom, J. Foley, R. Gress, and M. R. Bishop. 2008. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J. Clin. Oncol. 26: 5735-5741.
20. Thiant, S., M. Labalette, J. Trauet, V. Coiteux, E. de Berranger, J. P. Dessaint, and I. Yakoub-Agha. 2011. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 46: 1374-1381.
21. Matsuoka, K., H. T. Kim, S. McDonough, G. Bascug, B. Warshauer, J. Koreth, C. Cutler, V. T. Ho, E. P. Alyea, J. H. Antin, et al. 2010. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 120: 1479-1493.
22. Alpdogan, O., S. J. Muriglan, J. M. Eng, L. M. Willis, A. S. Greenberg, B. J. Kappel, and M. R. van den Brink. 2003. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 112: 1095-1107.
23. Perales, M. A., J. D. Goldberg, J. Yuan, G. Koehne, L. Lechner, E. B. Papadopoulos, J. W. Young, A. A. Jakubowski, B. Zaidi, H. Gallardo, et al. 2012. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 120: 4882-4891.
24. Dobin, A., C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, and T. R. Gingeras. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21.
25. Liao, Y., G. K. Smyth, and W. Shi. 2014. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30: 923-930.
26. RCoreTeam. 2014. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
27. Love, M. I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15: 550.
28. Cobbold, S. P. 2013. The mTOR pathway and integrating immune regulation. Immunology 140: 391-398.
29. Manning, B. D., and L. C. Cantley. 2007. AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
30. Rudd, C. E. 2006. Cell cycle 'check points' T cell anergy. Nat. Immunol. 7: 1130-1132.
31. Kuklina, E. M. 2013. Molecular mechanisms of T-cell anergy. Biochemistry (Mosc.) 78: 144-156.
32. Fathman, C. G., and N. B. Lineberry. 2007. Molecular mechanisms of CD4+ T-cell anergy. Nat. Rev. Immunol. 7: 599-609.
33. Wells, A. D. 2009. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J. Immunol. 182: 7331-7341.
34. Rosenberg, S. A., C. Sportès, M. Ahmadzadeh, T. J. Fry, L. T. Ngo, S. L. Schwarz, M. Stetler-Stevenson, K. E. Morton, S. A. Mavroukakis, M. Morre, et al. 2006. IL-7 administration to humans leads to expansion of CD8 + and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29: 313-319.
35. Sinha, M. L., T. J. Fry, D. H. Fowler, G. Miller, and C. L. Mackall. 2002. Interleukin 7 worsens graft-versus-host disease. Blood 100: 2642-2649.
36. Cox, A. L., S. A. Thompson, J. L. Jones, V. H. Robertson, G. Hale, H. Waldmann, D. A. Compston, and A. J. Coles. 2005. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35: 3332-3342.
37. Vercoulen, Y., E. J. Wehrens, N. H. van Teijlingen, W. de Jager, J. M. Beekman, and B. J. Prakken. 2009. Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells. PLoS One 4: e7183.
38. van Amelsfort, J. M., J. A. van Roon, M. Noordegraaf, K. M. Jacobs, J. W. Bijlsma, F. P. Lafeber, and L. S. Taams. 2007. Proinflammatory mediatorinduced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum. 56: 732-742.
39. Ruprecht, C. R., M. Gattorno, F. Ferlito, A. Gregorio, A. Martini, A. Lanzavecchia, and F. Sallusto. 2005. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. 201: 1793-1803.
40. Heninger, A. K., A. Theil, C. Wilhelm, C. Petzold, N. Huebel, K. Kretschmer, E. Bonifacio, and P. Monti. 2012. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J. Immunol. 189: 5649-5658.
41. Crellin, N. K., R. V. Garcia, and M. K. Levings. 2007. Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 109: 2014-2022.
42. Shrestha, S., K. Yang, C. Guy, P. Vogel, G. Neale, and H. Chi. 2015. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16: 178-187.
43. Sauer, S., L. Bruno, A. Hertweck, D. Finlay, M. Leleu, M. Spivakov, Z. A. Knight, B. S. Cobb, D. Cantrell, E. O'Connor, et al. 2008. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 105: 7797-7802.
44. Procaccini, C., M. Galgani, V. De Rosa, and G. Matarese. 2012. Intracellular metabolic pathways control immune tolerance. Trends Immunol. 33: 1-7.
45. Zheng, Y., S. L. Collins, M. A. Lutz, A. N. Allen, T. P. Kole, P. E. Zarek, and J. D. Powell. 2007. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 178: 2163-2170.
46. Duré, M., and F. Macian. 2009. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol. Immunol. 46: 999-1006.
47. Marcais, A., R. Blevins, J. Graumann, A. Feytout, G. Dharmalingam, T. Carroll, I. F. Amado, L. Bruno, K. Lee, T. Walzer, et al. 2014. microRNA-mediated regulation of mTOR complex components facilitates discrimination between activation and anergy in CD4 T cells. J. Exp. Med. 211: 2281-2295.
48. Huang, Y. H., D. K. Sojka, and D. J. Fowell. 2012. Cutting edge: Regulatory T cells selectively attenuate, not terminate, T cell signaling by disrupting NF-kB nuclear accumulation in CD4 T cells. J. Immunol. 188: 947-951.
49. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
50. Lechler, R., J. G. Chai, F. Marelli-Berg, and G. Lombardi. 2001. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology 103: 262-269.